 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...164165166167168169170171172173174...208209» |
- umbralisib (TGR-1202) / TG Therap, Utuxin (ublituximab) / TG Therap, TG-1701 / TG Therap
[VIRTUAL] Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_901;
P1
The combination of 1701+U2 has shown promising clinical activity and enhanced depth of response over TG-1701 monotherapy with no additional toxicity in patients with B-cell malignancy. Recruitment to this study (NCT03671590) continues.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P1 trial: Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers (clinicaltrials.gov) - Nov 4, 2020
P1, N=6, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial. (Pubmed Central) - Nov 4, 2020
Pathway analysis supports that Apatinib can be repurposed for the treatment of LA. Our results suggested that AM could be a potential option for advanced progressed LA patients to combat EGFR-TKI resistance.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial, Real-world evidence: LION-EC: A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer (clinicaltrials.gov) - Nov 3, 2020
P, N=1030, Not yet recruiting, Sponsor: Peking University
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Nov 2, 2020
P3, N=581, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer (clinicaltrials.gov) - Nov 2, 2020
P2, N=31, Not yet recruiting, Sponsor: Fudan University
- || Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, Lonquex (lipegfilgrastim biosimilar) / Teva
Retrospective data, Review, Journal: Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis. (Pubmed Central) - Nov 2, 2020
Mecapegfilgrastim, balugrastim, lipegfilgrastim and L-G-CSF biosimilar were best G-CSF drugs in reducing BP (cumulative probabilities: 20%, 14%, 8%, 8%, respectively). Mecapegfilgrastim, lipegfilgrastim and balugrastim might be the most appreciate G-CSF drugs with both good efficacy and tolerability when treating cancer patients after cytotoxic chemotherapy.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial completion date, Trial primary completion date: Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (clinicaltrials.gov) - Nov 1, 2020
P2, N=200, Recruiting, Sponsor: Shandong Provincial Hospital
Mecapegfilgrastim, lipegfilgrastim and balugrastim might be the most appreciate G-CSF drugs with both good efficacy and tolerability when treating cancer patients after cytotoxic chemotherapy. Not yet recruiting --> Recruiting | Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Oct 2020 --> Oct 2021
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron
Journal: VEGF Trap Suspended in the Semifluorinated Alkane F6H8 Inhibits Inflammatory Corneal Hem- and Lymphangiogenesis. (Pubmed Central) - Nov 1, 2020
The purpose of this study was to test the effect of vascular endothelial growth factor (VEGF) Trap suspended in the SFA perfluorohexyloctane (Trap/F6H8) on corneal neovascularization...Our findings might open new treatment avenues for local anti-angiogenic therapy at the cornea, as F6H8 is already approved for the usage at the ocular surface. With this study we show for the first time that SFAs can serve as carriers for anti-angiogenic drugs at the ocular surface.
- || Baize'an (tislelizumab) / BeiGene, Novartis, Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus, AiRuiKa (camrelizumab) / Incyte
Clinical, Journal, Monotherapy: The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. (Pubmed Central) - Nov 1, 2020
These findings emphasize that liver metastasis is a poor prognostic factor for advanced melanoma treated with anti-PD-1 monotherapy. Further exploration is still needed to find a new treatment approach for these patients.
- || imrecoxib (BAP 909) / Jiangsu Hengrui Medicine
Clinical, PK/PD data, Journal: Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. (Pubmed Central) - Oct 30, 2020
The 90% CIs of the GMRs of AUC C and INR were all within a 0.8-1.25 interval. The combination of warfarin and imrecoxib did not impact the pharmacodynamics and pharmacokinetics of single-dose warfarin; therefore, when treating a patient with imrecoxib and warfarin, it is not required to adjust the dosage of warfarin.
- ||| AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Trial completion, Trial completion date, Trial primary completion date: A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Oct 29, 2020
P2, N=105, Completed, Sponsor: Reistone Biopharma Company Limited
The combination of warfarin and imrecoxib did not impact the pharmacodynamics and pharmacokinetics of single-dose warfarin; therefore, when treating a patient with imrecoxib and warfarin, it is not required to adjust the dosage of warfarin. Recruiting --> Completed | Trial completion date: Dec 2020 --> Aug 2020 | Trial primary completion date: Dec 2020 --> Aug 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial, PD(L)-1 Biomarker: Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma (clinicaltrials.gov) - Oct 29, 2020
P, N=30, Not yet recruiting, Sponsor: Peking University First Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New trial: Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC (clinicaltrials.gov) - Oct 29, 2020
P, N=200, Not yet recruiting, Sponsor: Shandong Cancer Hospital and Institute
- |||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 29, 2020
P2, N=117, Recruiting, Sponsor: Peking University
- AiRuiKa (camrelizumab) / Incyte, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] A randomised, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in locally advanced NSCLC (Channel 3) - Oct 29, 2020 - Abstract #ESMOIO2020ESMO_IO_237;
P2
Conclusions These interim results suggested camrelizumab plus CT may have a better effect as neoadjuvant therapy in locally advanced NSCLC. This trial is ongoing and final analysis will be conducted after study completion.
- || AiRuiKa (camrelizumab) / Incyte
Clinical, P2 data, Journal: A single-arm, multicenter, phase 2 study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. (Pubmed Central) - Oct 28, 2020
P2
This trial is ongoing and final analysis will be conducted after study completion. Camrelizumab demonstrated high response rate, durable response and controllable safety in Chinese patients with relapsed or refractory cHL, becoming a new safe and effective treatment option in this setting.
- ||| Arzerra (ofatumumab) / Novartis, Genmab, Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharma
Clinical: At this point, flumatinib will have to be extremely well-tolerated, much cheaper, and most importantly, provide a clinical benefit that the others are lacking to replace any of the above. Otherwise it’s just gonna be another ofatumumab. (Twitter) - Oct 28, 2020
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial, Metastases: Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 27, 2020
P2, N=208, Recruiting, Sponsor: Sun Yat-sen University
- |||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 27, 2020
P2, N=62, Recruiting, Sponsor: Sun Yat-sen University
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, P2 data, Journal: A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer. (Pubmed Central) - Oct 27, 2020
Conclusion Apatinib combination/maintenance therapy showed promising efficacy and safety to extend OS/PFS in ED-SCLC and will be a potent therapeutic option in future practice. Although the scale of this study is small, further research on large sample sizes is needed.
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Enrollment open, Trial completion date, Trial primary completion date: SHR0302 and Steroid As First Line Therapy for Chronic GVHD (clinicaltrials.gov) - Oct 26, 2020
P1, N=30, Recruiting, Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Although the scale of this study is small, further research on large sample sizes is needed. Not yet recruiting --> Recruiting | Trial completion date: Nov 2021 --> May 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
- |||| AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New P2 trial: A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC (clinicaltrials.gov) - Oct 26, 2020
P2, N=150, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
Journal: Anti-PD-1 plus a VEGFR2 Inhibitor Shows Promise in Cervical Cancer. (Pubmed Central) - Oct 26, 2020
Not yet recruiting --> Recruiting | Trial completion date: Nov 2021 --> May 2022 | Trial primary completion date: Nov 2021 --> Apr 2022 The PD-1 antibody camrelizumab plus the VEGFR2 inhibitor apatinib had efficacy in a phase II trial.
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: Remimazolam Tosilate Sedation and Midazolam Sedation in Dental Patients (clinicaltrials.gov) - Oct 25, 2020
P4, N=40, Not yet recruiting, Sponsor: Peking University
- | Journal: Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma. (Pubmed Central) - Oct 25, 2020
HSN608 inhibited the growth of CCDC6-RET driven LC-2/ad cell line with IC50 of ~3 nM. Under similar conditions, BLU667 and vandetanib (two drugs being evaluated against RET-driven cancers in the clinic) inhibited the growth of LC-2/ad with IC50 values of ~10 and 328 nM respectively.
- | plinabulin (BPI 2358) / BeyondSpring
Journal: GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. (Pubmed Central) - Oct 25, 2020
In cancer patients, high expression of the GEF-H1 immune gene signature is associated with prolonged survival. Our study identifies an alternate intracellular axis in DCs induced upon microtubule destabilization in which GEF-H1 promotes protective anti-tumor immunity.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC (clinicaltrials.gov) - Oct 22, 2020
P2, N=40, Completed, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Our study identifies an alternate intracellular axis in DCs induced upon microtubule destabilization in which GEF-H1 promotes protective anti-tumor immunity. Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Aug 2019 --> Dec 2019
- || otesaconazole (VT-1161) / Mycovia Pharma
REVIVE: oral VT-1161 for acute and recurrent vulvovaginal candidiasis. https://t.co/D4hNl3DJKP #idweek2020 (Twitter) - Oct 22, 2020
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal, Monotherapy: Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer. (Pubmed Central) - Oct 21, 2020
The toxicities associated with apatinib were generally acceptable with a total grade 3/4 toxicity of 50%. Apatinib is an optional choice as salvage treatment in elderly patients with advanced metastatic NSCLC, with modest efficacy and acceptable toxicities.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Trial completion date: Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer (clinicaltrials.gov) - Oct 19, 2020
P1/2, N=30, Active, not recruiting, Sponsor: Wuhan Union Hospital, China
Apatinib is an optional choice as salvage treatment in elderly patients with advanced metastatic NSCLC, with modest efficacy and acceptable toxicities. Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2022
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract (clinicaltrials.gov) - Oct 19, 2020
P2, N=40, Not yet recruiting, Sponsor: Fudan University
- ||||||| AiTan (rivoceranib) / HLB Bio Group
Trial completion, Metastases: ANGEL: A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (clinicaltrials.gov) - Oct 19, 2020
P3, N=460, Completed, Sponsor: Elevar Therapeutics
Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2022 Active, not recruiting --> Completed
- |||| NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Enrollment open: Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study) (clinicaltrials.gov) - Oct 19, 2020
P3, N=200, Recruiting, Sponsor: Bausch Health Americas, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811-I-101: A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - Oct 19, 2020
P1, N=226, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma (clinicaltrials.gov) - Oct 19, 2020
P2, N=60, Recruiting, Sponsor: Sun Yat-sen University
- | SHR2150 / Jiangsu Hengrui Pharma
New P1/2 trial, First-in-human: Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors (clinicaltrials.gov) - Oct 19, 2020
P1/2, N=50, Recruiting, Sponsor: Chinese PLA General Hospital
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
New trial: Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) - Oct 18, 2020
P, N=200, Not yet recruiting, Sponsor: Nanfang Hospital of Southern Medical University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer (clinicaltrials.gov) - Oct 18, 2020
P2, N=58, Recruiting, Sponsor: Zhongshan Hospital Xiamen University
- pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
[VIRTUAL] Response of an ERBB2 Exon 20 Insertion Mutation Breast Cancer to Pyrotinib (On-Demand e-Poster Display) - Oct 18, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1489;
- pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
[VIRTUAL] Response of an ERBB2 Exon 20 Insertion Mutation Breast Cancer to Pyrotinib (On-Demand e-Poster Display) - Oct 18, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1476;
- |||| perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
#Novaliq Gmbh has had medical devices (#NovaTears,#EvoTears eye drops) manufactured by non-compliant companies. In the factory of horrors Miteni Spa, workers forced to Read on here https://t.co/Ff7z6we1KW (Twitter) - Oct 17, 2020
- || AiTan (rivoceranib) / HLB Bio Group, Opdivo (nivolumab) / Ono Pharma, BMS, AiRuiKa (camrelizumab) / Incyte
Clinical, P2 data, Journal: Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. (Pubmed Central) - Oct 15, 2020
Grade 3 AEs were observed in nine patients (9/10, 90%), and the commonest was hypertension (30%). In conclusion, SHR-1210 combined with apatinib has failed to improve the efficacy of treatment of MSS mCRC, and the intolerable toxicity may be the leading cause.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer () - Oct 14, 2020 - Abstract #SITC2020SITC_1470;
While patients with RCCEP derived greater benefit from camrelizumab. Further studies are needed in large sample size trials.
- Tyvyt (sintilimab) / Eli Lilly, AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor () - Oct 14, 2020 - Abstract #SITC2020SITC_1360;
P2
This study is registered with ClinicalTrials.gov, number NCT04282278. Results N/A Conclusions N/A
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab monotherapy or combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma：a retrospective study () - Oct 14, 2020 - Abstract #SITC2020SITC_1221;
RCCEP occurrence was positively associated with outcomes of camrelizumab. Further studies are needed to verify this data.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Anlyasis of Therapeutic effect and safty of PD-1 Inhibitors in Clinical treatment of Oral and Maxillofacial malignant tumors () - Oct 14, 2020 - Abstract #SITC2020SITC_1217;
Among the 33 patients, 5 patients had immune-related adverse reactions (15.2%), including 2 cases of skin rash, 1 case of skin capillary hyperplasia and 2 cases of other adverse reactions. Conclusions The patients with Oral malignant tumor treated with PD-1 inhibitor Camrelizumab injection combined with targeted drug apatinib or postoperative adjuvant therapy can effectively control tumor development, improve the survival of patients, and help to improve the stability of postoperative efficacy.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer () - Oct 14, 2020 - Abstract #SITC2020SITC_735;
While patients with RCCEP derived greater benefit from camrelizumab. Further studies are needed in large sample size trials.
- Tyvyt (sintilimab) / Eli Lilly, AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor () - Oct 14, 2020 - Abstract #SITC2020SITC_625;
P2
This study is registered with ClinicalTrials.gov, number NCT04282278. Results N/A Conclusions N/A
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab monotherapy or combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma：a retrospective study () - Oct 14, 2020 - Abstract #SITC2020SITC_486;
RCCEP occurrence was positively associated with outcomes of camrelizumab. Further studies are needed to verify this data.